ACM
TAK icon

Allred Capital Management’s Takeda Pharmaceutical TAK Stock Holding History

Allred Capital Management’s Portfolio TAK Stock Details TAK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-403
Closed -$7.95K – 642
2019
Q4 		$7.95K Buy
+403
New +$7.71K ﹤0.01% 615

Other funds holding TAK

GCM
Glenview Capital Management New York $3.98B AUM 20.52% 1-Year Est. Return
PC
Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return
AC
Adelphi Capital London, United Kingdom $3.21M AUM 121.6% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
GC
GMT Capital Atlanta, Georgia $2.19B AUM 72.3% 1-Year Est. Return
LP
LMR Partners London, United Kingdom $45.4B AUM 60.68% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Allred Capital Management's TAK Position: Q1 2020 in Review

Allred Capital Management sold out of Takeda Pharmaceutical (TAK) in Q1 2020, closing a stake of 403 shares — an estimated $7.95K sold.

Allred Capital Management first reported a position in TAK in Q4 2019 and held it in 1 quarter. The position peaked at $7.95K in Q4 2019. 313 funds tracked by Wall St. Rank hold TAK as of Q1 2020.

  • Allred Capital Management reported no remaining Takeda Pharmaceutical position as of Q1 2020 after selling out during the quarter.
  • Allred Capital Management sold 403 Takeda Pharmaceutical shares in Q1 2020, an estimated $7.95K.
  • Allred Capital Management first reported a position in Takeda Pharmaceutical in Q4 2019 and held it in 1 quarter.
  • Allred Capital Management's Takeda Pharmaceutical position peaked at $7.95K in Q4 2019.
  • 313 funds tracked by Wall St. Rank held Takeda Pharmaceutical as of Q1 2020.

Based on Allred Capital Management's 13F filing for Q1 2020, filed 17 Apr 2020.